

HR 5030

DIVERSE Trials Act

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Aug 13, 2021

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Aug 16, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/5030>

Sponsor

Name: Rep. Ruiz, Raul [D-CA-36]

Party: Democratic • **State:** CA • **Chamber:** House

Cosponsors (54 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Bucshon, Larry [R-IN-8]	R · IN		Aug 13, 2021
Rep. Bonamici, Suzanne [D-OR-1]	D · OR		May 6, 2022
Rep. Brownley, Julia [D-CA-26]	D · CA		May 6, 2022
Rep. Higgins, Brian [D-NY-26]	D · NY		May 6, 2022
Rep. Larson, John B. [D-CT-1]	D · CT		May 6, 2022
Rep. Mfume, Kweisi [D-MD-7]	D · MD		May 6, 2022
Rep. Ross, Deborah K. [D-NC-2]	D · NC		May 6, 2022
Rep. Rush, Bobby L. [D-IL-1]	D · IL		May 6, 2022
Rep. Salazar, Maria Elvira [R-FL-27]	R · FL		May 6, 2022
Rep. Soto, Darren [D-FL-9]	D · FL		May 6, 2022
Rep. Beatty, Joyce [D-OH-3]	D · OH		Jul 1, 2022
Rep. Blunt Rochester, Lisa [D-DE-At Large]	D · DE		Jul 1, 2022
Rep. Carbajal, Salud O. [D-CA-24]	D · CA		Jul 1, 2022
Rep. Evans, Dwight [D-PA-3]	D · PA		Jul 1, 2022
Rep. Jayapal, Pramila [D-WA-7]	D · WA		Jul 1, 2022
Rep. Johnson, Eddie Bernice [D-TX-30]	D · TX		Jul 1, 2022
Rep. Napolitano, Grace F. [D-CA-32]	D · CA		Jul 1, 2022
Rep. Rutherford, John H. [R-FL-4]	R · FL		Jul 1, 2022
Rep. Blumenauer, Earl [D-OR-3]	D · OR		Jul 26, 2022
Rep. Cleaver, Emanuel [D-MO-5]	D · MO		Jul 26, 2022
Rep. Kahele, Kaiiali'i [D-HI-2]	D · HI		Jul 26, 2022
Rep. Jacobs, Sara [D-CA-53]	D · CA		Sep 9, 2022
Rep. Cherfilus-McCormick, Sheila [D-FL-20]	D · FL		Oct 4, 2022
Rep. Cicilline, David N. [D-RI-1]	D · RI		Oct 4, 2022
Rep. Davids, Sharice [D-KS-3]	D · KS		Oct 4, 2022
Rep. Harder, Josh [D-CA-10]	D · CA		Oct 4, 2022
Rep. Khanna, Ro [D-CA-17]	D · CA		Oct 4, 2022
Rep. Kilmer, Derek [D-WA-6]	D · WA		Oct 4, 2022
Rep. Kuster, Ann M. [D-NH-2]	D · NH		Oct 4, 2022
Rep. Langevin, James R. [D-RI-2]	D · RI		Oct 4, 2022
Rep. Lawrence, Brenda L. [D-MI-14]	D · MI		Oct 4, 2022
Rep. Levin, Mike [D-CA-49]	D · CA		Oct 4, 2022
Rep. Lynch, Stephen F. [D-MA-8]	D · MA		Oct 4, 2022
Rep. Matsui, Doris O. [D-CA-6]	D · CA		Oct 4, 2022
Rep. McGovern, James P. [D-MA-2]	D · MA		Oct 4, 2022
Rep. O'Halleran, Tom [D-AZ-1]	D · AZ		Oct 4, 2022
Rep. Omar, Ilhan [D-MN-5]	D · MN		Oct 4, 2022
Rep. Posey, Bill [R-FL-8]	R · FL		Oct 4, 2022
Rep. Quigley, Mike [D-IL-5]	D · IL		Oct 4, 2022
Rep. Ryan, Tim [D-OH-13]	D · OH		Oct 4, 2022
Rep. Sherrill, Mikie [D-NJ-11]	D · NJ		Oct 4, 2022

Cosponsor	Party / State	Role	Date Joined
Rep. Swalwell, Eric [D-CA-15]	D · CA		Oct 4, 2022
Rep. Underwood, Lauren [D-IL-14]	D · IL		Oct 4, 2022
Rep. Welch, Peter [D-VT-At Large]	D · VT		Oct 4, 2022
Rep. Cohen, Steve [D-TN-9]	D · TN		Oct 31, 2022
Rep. Kildee, Daniel T. [D-MI-5]	D · MI		Oct 31, 2022
Rep. Malinowski, Tom [D-NJ-7]	D · NJ		Oct 31, 2022
Rep. Pappas, Chris [D-NH-1]	D · NH		Oct 31, 2022
Rep. Waters, Maxine [D-CA-43]	D · CA		Oct 31, 2022
Rep. Crow, Jason [D-CO-6]	D · CO		Dec 15, 2022
Rep. DeSaulnier, Mark [D-CA-11]	D · CA		Dec 15, 2022
Rep. Pocan, Mark [D-WI-2]	D · WI		Dec 15, 2022
Rep. Porter, Katie [D-CA-45]	D · CA		Dec 15, 2022
Rep. Lee, Barbara [D-CA-13]	D · CA		Dec 23, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Aug 16, 2021
Ways and Means Committee	House	Referred to	Aug 13, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 S 4486	Related bill	Jun 23, 2022: Read twice and referred to the Committee on Finance.
117 S 2706	Identical bill	Aug 10, 2021: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Diversifying Investigations Via Equitable Research Studies for Everyone Trials Act or the DIVERSE Trials Act

This bill requires activities to increase diversity in clinical trials. It also expands reporting by laboratories that test for and diagnose COVID-19 and requires a study on data collection and data sharing during public health emergencies.

Specifically, the Food and Drug Administration (FDA) must issue guidance on decentralized clinical trials to promote meaningful demographic and geographic diversity in patient engagement, enrollment, and participation. Decentralized clinical trials include those executed through telemedicine or other digital technologies to allow for the remote collection and assessment of clinical trial data. The FDA may also work with foreign regulators to harmonize international regulations governing decentralized clinical trials and the use of digital health technology.

In addition, the Department of Health and Human Services (HHS) may support community education, outreach, and recruitment activities for clinical trials of treatments for conditions that disproportionately impact populations underrepresented in clinical trials.

The bill also specifies that drug or device manufacturers may provide, subject to some limits, free digital health technologies and other remuneration to patients in approved clinical trials without violating laws that address fraud and abuse in federal programs.

Furthermore, laboratories that test for and diagnose COVID-19 must report additional demographic data, including information about social determinants of health. HHS must also contract with the National Academy of Medicine to study and propose a design for an interoperable platform to facilitate data sharing during public health emergencies.

Actions Timeline

- **Aug 16, 2021:** Referred to the Subcommittee on Health.
- **Aug 13, 2021:** Introduced in House
- **Aug 13, 2021:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Aug 13, 2021:** Referred to the Subcommittee on Health.